アルツハイマー病の診断と予後のためのマルチモダル技術

Richard J Perrin¹, Anne M Fagan, David M Holtzman

¹Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.

Nature

|October 16, 2009

まとめ

アルツハイマー病は,認知症になる数年前の脳タンパク質の誤折りによるものです. 新しいイメージングとバイオマーカー技術は,この神経変性疾患の早期発見と介入を可能にします.

科学分野:

神経科学は神経科学である.
神経学神経学とは
バイオケミストリーバイオケミストリー

背景:

アルツハイマー病 (AD) は,何百万人に及ぶ世界的な健康問題です.
ADの特徴は,タンパク質の誤折り,それに続く脳損傷で,認知症の発症に先立ちます.
現在の治療法では,アルツハイマー病の進行を予防したり遅らせたりできません.

研究の目的:

アルツハイマー病の病理学の臨床前検出における進歩を強調する.
早期のメカニズムベースの治療介入の可能性を強調する.
アルツハイマー病の将来の臨床試験の設計を参考にするために.

主な方法:

新しい神経イメージング技術を活用したものです.
先進的な液体バイオマーカー分析を使用しています.
アルツハイマー病の臨床前段階を調査する.

主要な成果:

アルツハイマー病の病理学は,臨床前段階で検出可能である.
新しい診断ツールにより,ADの早期発見が期待されています.
早期発見は,適切な治療戦略を間に合うように促進します.

結論:

神経画像とバイオマーカーの進歩により,アルツハイマー病の臨床前検出が可能になりました.
早期発見は,メカニズムに基づく治療への道を開く.
これらの開発は,効果的なアルツハイマー病の臨床試験の設計に不可欠です.

さらに関連する動画

09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

2.0K

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

1.1K

関連する概念動画

01:26

Alzheimer's Disease: Overview

1.7K

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

1.7K

01:22

Alzheimer's Disease: Treatment

1.3K

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

1.3K

01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...

01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

関連する実験動画